Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Controversies in stage I NSCLC

When is surgery the only best approach for stage I NSCLC and when should we consider systemic adjuvant therapy


21 Mar 2024


Controversies in stage I NSCLC


Targeted Therapy;  Immunotherapy;  Radiation Oncology;  Surgical Oncology

Tumour Site

Non-Small Cell Lung Cancer


Hisao Asamura


H. Asamura

Author affiliations

  • Keio University School of Medicine, 160-8582 - Shinjuku-ku/JP


This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.